{"id":"NCT04674761","sponsor":"Albireo","briefTitle":"Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome","officialTitle":"A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-03-19","primaryCompletion":"2022-09-09","completion":"2022-09-09","firstPosted":"2020-12-19","resultsPosted":"2023-11-02","lastUpdate":"2023-11-02"},"enrollment":52,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Alagille Syndrome"],"interventions":[{"type":"DRUG","name":"Odevixibat","otherNames":["A4250"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Odevixibat (A4250)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.","primaryOutcome":{"measure":"Change From Baseline in Scratching Score","timeFrame":"Change from baseline for each four-week average pruritis score to Month 6 (Weeks 21 to 24), in which baseline was calculated based on the 14 days before the start of treatment.","effectByArm":[{"arm":"Odevixibat (A4250)","deltaMin":-1.69,"sd":0.174},{"arm":"Placebo","deltaMin":-0.8,"sd":0.233}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0012"}]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":32,"countries":["United States","Belgium","Canada","France","Germany","Israel","Italy","Malaysia","Netherlands","New Zealand","Poland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["38670135"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":35},"commonTop":["Pyrexia","Diarrhoea","COVID-19","Abdominal pain","Upper respiratory tract infection"]}}